Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 92539P101 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Biotechnology Value Fund L P
13G/A
Amendment 1
|
0% |
8/14/2025
Event 6/30/2025
|
|
| Biotechnology Value Fund L P | 0% | ||
| BVF I GP LLC | 0% | ||
| Biotechnology Value Fund II LP | 0% | ||
| BVF II GP LLC | 0% | ||
| Biotechnology Value Trading Fund OS LP | 0% | ||
| BVF Partners OS Ltd. | 0% | ||
| BVF GP Holdings LLC | 0% | ||
| BVF Partners L P/IL | 0% | ||
| BVF Inc/IL | 0% | ||
| Lampert Mark N | 0% | ||
|
Pentwater Capital Management LP
13G
|
7.5% |
8/14/2025
Event 6/30/2025
|
|
| Pentwater Capital Management LP | 7.5% | ||
| Matthew Halbower | 7.5% | ||
|
GV 2017, L.P.
13G/A
Amendment 3
|
0% |
7/28/2025
Event 7/25/2025
|
|
| GV 2017, L.P. | 0% | ||
| GV 2017 GP, L.P. | 0% | ||
| GV 2017 GP, L.L.C. | 0% | ||
| GV 2019, L.P. | 0% | ||
| GV 2019 GP, L.P. | 0% | ||
| GV 2019 GP, L.L.C. | 0% | ||
| GV 2023, L.P. | 0% | ||
| GV 2023 GP, L.P. | 0% | ||
| GV 2023 GP, L.L.C. | 0% | ||
| Alphabet Holdings LLC | 0% | ||
| Verily Life Sciences LLC | 0% | ||
| XXVI Holdings Inc. | 0% | ||
| Alphabet Inc. | 0% | ||
|
Millennium Management LLC
13G
|
4.9% |
4/29/2025
Event 4/22/2025
|
|
| Millennium Management LLC | 4.9% | ||
| Millennium Group Management LLC | 4.9% | ||
| Israel A. Englander | 4.9% | ||
| BlackRock, Inc. 13G/A Amendment 2 | 7.0% |
4/17/2025
Event 3/31/2025
|
|
| State Street Corp 13G | 3.8% |
2/5/2025
Event 12/31/2024
|
|
|
Millennium Management LLC
13G/A
Amendment 2
|
4.6% |
1/31/2025
Event 12/31/2024
|
|
| Integrated Core Strategies (US) LLC | 3.4% | ||
| Millennium Management LLC | 4.6% | ||
| Millennium Group Management LLC | 4.6% | ||
| Israel A. Englander | 4.6% | ||
| ARK Investment Management LLC 13G/A Amendment 2 | 0% |
1/10/2025
Event 9/30/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q4 | 1 | 24.0 k | $344 k |
| 2025 Q3 | 7 | 241 k | $1.37 M |
| 2025 Q2 | 190 | 73.0 M | $820 M |
| 2025 Q1 | 199 | 80.8 M | $369 M |
| 2024 Q4 | 176 | 78.7 M | $444 M |
| 2024 Q3 | 185 | 76.9 M | $373 M |
| 2024 Q2 | 175 | 78.5 M | $383 M |
| 2024 Q1 | 174 | 84.9 M | $1.13 B |
| 2023 Q4 | 169 | 77.6 M | $1.08 B |
| 2023 Q3 | 147 | 63.9 M | $847 M |
| 2023 Q2 | 130 | 61.9 M | $1.16 B |
| 2023 Q1 | 133 | 63.3 M | $912 M |
| 2022 Q4 | 133 | 67.1 M | $1.30 B |
| 2022 Q3 | 144 | 60.7 M | $2.08 B |
| 2022 Q2 | 105 | 45.6 M | $696 M |
| 2022 Q1 | 98 | 46.7 M | $1.06 B |
| 2021 Q4 | 102 | 45.2 M | $1.66 B |
| 2021 Q3 | 74 | 38.7 M | $1.81 B |
| 2021 Q2 | 70 | 37.7 M | $2.25 B |